Zolmitriptan oral dispersible film

Drug Profile

Zolmitriptan oral dispersible film

Alternative Names: zolmitriptan ODF; Zolmitriptan PharmaFilm; Zolmitriptan RapidFilm; Zolmitriptan Renantos 2.5mg Schmelzfilm; Zolmitriptan Renantos 5mg Schmelzfilm

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator APR Applied Pharma Research; Labtec
  • Developer APR Applied Pharma Research; Aquestive Therapeutics; tesa Labtec
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 17 Apr 2015 Zolmitriptan oral dispersible film is approved in the European Union for Migraine
  • 08 Feb 2012 Registered for Migraine in Austria (PO)
  • 08 Feb 2012 Registered for Migraine in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top